Skip to main content
Top
Published in: Endocrine 1/2019

01-01-2019 | Original Article

Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer

Authors: Domenico Albano, Maria Beatrice Panarotto, Rexhep Durmo, Carlo Rodella, Francesco Bertagna, Raffaele Giubbini

Published in: Endocrine | Issue 1/2019

Login to get access

Abstract

Purpose

Distant metastases (DM) from DTC occur in 5–25% of cases and are correlated to lower survival; the prognostic significance of the temporal onset of DM is unclear. Our aim was to retrospectively analyze the prevalence of DM and to assess the prognostic role of the timing of manifestation of DM regarding the outcome.

Materials and methods

We included 174 patients (mean age 64 years). According to the time of manifestation, DM were divided in two groups: synchronous DM (SDM, n = 108) defined as metastases present at initial diagnosis and metachronous DM (MDM, n = 66) as diagnosed during follow-up. SDM were further sub grouped in pre-RAIT when diagnosed during pre-surgery work-up (n = 35) and baseline-RAIT when detected by first whole body scan after RAIT (n = 73). Disease-specific survival (DSS) was analyzed using the Kaplan–Meier method.

Results

Total RAI activities and number of treatments were significantly higher in MDM, also loss of RAI avidity was more frequent in MDM. Forty-four patients died during follow-up, of which 41 were DTC-related deaths, 5-year and 10-year DSS were 80% and 56%. On univariate analysis MDM had significantly shorter DSS; also histotype and RAI avidity were significant risk factors of impaired survival. On multivariate analysis, only loss of RAI avidity remained as independent negative predictor (p = 0.043). Considering SDM, DSS was significantly shorter in pre-RAIT group than baseline-RAIT (p = 0.004). Instead there was no significant difference between pre-RAIT-SDM and MDM in survival outcome (p = 0.875).

Conclusions

In DTC with DM, loss of RAI uptake has an important role in survival. No significant difference in survival outcome was discovered between SDM and MDM; but, among SDM, pre-RAIT had significant shorter DSS than baseline-RAIT.
Literature
2.
go back to reference B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral
3.
go back to reference E.P. Simard, E.M. Ward, R. Siegel, A. Jemal, Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J. Clin. 62, 118–128 (2012)CrossRefPubMed E.P. Simard, E.M. Ward, R. Siegel, A. Jemal, Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J. Clin. 62, 118–128 (2012)CrossRefPubMed
4.
go back to reference E. Sampson, J.D. Brierley, L.W. Le, L. Rotstein, R.W. Tsang, Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110, 1451–1456 (2007)CrossRefPubMed E. Sampson, J.D. Brierley, L.W. Le, L. Rotstein, R.W. Tsang, Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110, 1451–1456 (2007)CrossRefPubMed
5.
go back to reference M. Schlumberger, M. Tubiana, F. De Vathaire, C. Hill, P. Gardet, J.P. Travagli et al. Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 63, 960–967 (1986)CrossRefPubMed M. Schlumberger, M. Tubiana, F. De Vathaire, C. Hill, P. Gardet, J.P. Travagli et al. Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 63, 960–967 (1986)CrossRefPubMed
6.
go back to reference D. Albano, F. Bertagna, M. Bertoli, M. Bonacina, R. Durmo, E. Cerudelli et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. Eur. J. Endo. (2018) https://doi.org/10.1530/EJE-18-0253 D. Albano, F. Bertagna, M. Bertoli, M. Bonacina, R. Durmo, E. Cerudelli et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. Eur. J. Endo. (2018) https://​doi.​org/​10.​1530/​EJE-18-0253
7.
go back to reference M. Haq, C. Harmer, Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin. Endocrinol. 63, 87–93 (2005)CrossRef M. Haq, C. Harmer, Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin. Endocrinol. 63, 87–93 (2005)CrossRef
8.
go back to reference F.A. Verburg, M. Luster, Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best. Pract. Res Clin. Endocrinol. Metab. 31, 279–290 (2017)CrossRefPubMed F.A. Verburg, M. Luster, Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best. Pract. Res Clin. Endocrinol. Metab. 31, 279–290 (2017)CrossRefPubMed
9.
go back to reference M. Shoup, A. Stojadinovic, A. Nissan, R.A. Ghossein, S. Freedman, M.F. Brennan et al. Prognostic indicators of outcomes in patients with distantmetastasesfromdifferentiated thyroid carcinoma. J. Am. Coll. Surg. 197, 191–197 (2003)CrossRefPubMed M. Shoup, A. Stojadinovic, A. Nissan, R.A. Ghossein, S. Freedman, M.F. Brennan et al. Prognostic indicators of outcomes in patients with distantmetastasesfromdifferentiated thyroid carcinoma. J. Am. Coll. Surg. 197, 191–197 (2003)CrossRefPubMed
10.
go back to reference A. Stojadinovic, M. Shoup, R.A. Ghossein, A. Nissan, M.F. Brennan, J.P. Shah et al. The role of operations for distantly metastatic well-differentiated thyroid carcinoma. Surgery 131, 636–643 (2002)CrossRefPubMed A. Stojadinovic, M. Shoup, R.A. Ghossein, A. Nissan, M.F. Brennan, J.P. Shah et al. The role of operations for distantly metastatic well-differentiated thyroid carcinoma. Surgery 131, 636–643 (2002)CrossRefPubMed
11.
go back to reference J.M. Mihailovic, L.J. Stefanovic, M.D. Malesevic, M.D. Erak, D.D. Tesanovic, Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl. Med. Commun. 30, 558–564 (2009)CrossRefPubMed J.M. Mihailovic, L.J. Stefanovic, M.D. Malesevic, M.D. Erak, D.D. Tesanovic, Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl. Med. Commun. 30, 558–564 (2009)CrossRefPubMed
12.
go back to reference Y. Orita, I. Sugitani, M. Matsuura, M. Ushijima, K. Tsukahara, Y. Fujimoto et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 147, 424–431 (2010)CrossRefPubMed Y. Orita, I. Sugitani, M. Matsuura, M. Ushijima, K. Tsukahara, Y. Fujimoto et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 147, 424–431 (2010)CrossRefPubMed
13.
go back to reference F. Pitoia, F. Bueno, G. Cross, Long-term survival and low-effective cumulative radioiodine doses to achieve remission in patients with 131iodine-avid lung metastasis from differentiated thyroid cancer. Clin. Nucl. Med. 39, 784–790 (2014)CrossRefPubMed F. Pitoia, F. Bueno, G. Cross, Long-term survival and low-effective cumulative radioiodine doses to achieve remission in patients with 131iodine-avid lung metastasis from differentiated thyroid cancer. Clin. Nucl. Med. 39, 784–790 (2014)CrossRefPubMed
14.
go back to reference A. Sabet, I. Binse, S. Dogan, A. Koch, S.J. Rosenbaum-Krumme, H.J. Biersack et al. Distinguishing sinchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 44, 190–195 (2017)CrossRefPubMed A. Sabet, I. Binse, S. Dogan, A. Koch, S.J. Rosenbaum-Krumme, H.J. Biersack et al. Distinguishing sinchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 44, 190–195 (2017)CrossRefPubMed
15.
go back to reference M. Luster, S.E. Clarke, M. Dietlein, M. Lassmann, P. Lind, W.J. Oyen et al. European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941–1959 (2008)CrossRefPubMed M. Luster, S.E. Clarke, M. Dietlein, M. Lassmann, P. Lind, W.J. Oyen et al. European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941–1959 (2008)CrossRefPubMed
16.
go back to reference S.B. Edge, D.R. Byrd, C.C. Compton, A. G. Fritz, F. L. Greene, A. Trotti (eds.) AJCC Cancer Staging Manual. 7th edn. (Springer, New York, 2010). S.B. Edge, D.R. Byrd, C.C. Compton, A. G. Fritz, F. L. Greene, A. Trotti (eds.) AJCC Cancer Staging Manual. 7th edn. (Springer, New York, 2010).
17.
go back to reference J. Lee, E.Y. Soh, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann. Surg. 251, 114–119 (2010)CrossRefPubMed J. Lee, E.Y. Soh, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann. Surg. 251, 114–119 (2010)CrossRefPubMed
18.
go back to reference B.H. Lang, K.P. Wong, C.Y. Cheung, K.Y. Wan, C.Y. Lo, Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann. Surg. Oncol. 20, 1329–1335 (2013)CrossRefPubMed B.H. Lang, K.P. Wong, C.Y. Cheung, K.Y. Wan, C.Y. Lo, Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann. Surg. Oncol. 20, 1329–1335 (2013)CrossRefPubMed
19.
go back to reference I.J. Nixon, M.M. Whitcher, F.L. Palmer, R.M. Tuttle, A.R. Shaha, J.P. Shah et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22, 884–889 (2012)CrossRefPubMedPubMedCentral I.J. Nixon, M.M. Whitcher, F.L. Palmer, R.M. Tuttle, A.R. Shaha, J.P. Shah et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22, 884–889 (2012)CrossRefPubMedPubMedCentral
20.
go back to reference S.F. Dinneen, M.J. Valimaki, E.J. Bergstralh, J.R. Goellner, C.A. Gorman, I.D. Hay, Distant metastases in papillary thyroidcarcinoma:100 cases observed at one institution during 5 decades. J. Clin. Endocrinol. Metab. 80, 2041–2045 (1995)PubMed S.F. Dinneen, M.J. Valimaki, E.J. Bergstralh, J.R. Goellner, C.A. Gorman, I.D. Hay, Distant metastases in papillary thyroidcarcinoma:100 cases observed at one institution during 5 decades. J. Clin. Endocrinol. Metab. 80, 2041–2045 (1995)PubMed
21.
go back to reference C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)CrossRefPubMed C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)CrossRefPubMed
22.
go back to reference U. Feine, R. Lietzenmayer, J.P. Hanke, H. Wöhrle, W. Müller-Schauenburg, 18FDG whole body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34, 127–134 (1995)CrossRefPubMed U. Feine, R. Lietzenmayer, J.P. Hanke, H. Wöhrle, W. Müller-Schauenburg, 18FDG whole body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34, 127–134 (1995)CrossRefPubMed
23.
go back to reference F. Bertagna, D. Albano, G. Bosio, A. Piccardo, B. Dib, R. Giubbini, 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. it’s value confirmed by a bicentric experience. Curr. Radiopharm. 9, 228–234 (2016)CrossRefPubMed F. Bertagna, D. Albano, G. Bosio, A. Piccardo, B. Dib, R. Giubbini, 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. it’s value confirmed by a bicentric experience. Curr. Radiopharm. 9, 228–234 (2016)CrossRefPubMed
24.
go back to reference C.I. Lundgren, P. Hall, P.W. Dickman, J. Zedenius, Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case–control study. Cancer 106, 524–531 (2006)CrossRefPubMed C.I. Lundgren, P. Hall, P.W. Dickman, J. Zedenius, Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case–control study. Cancer 106, 524–531 (2006)CrossRefPubMed
25.
go back to reference I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114, 1050–1057 (1993)PubMed I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114, 1050–1057 (1993)PubMed
26.
go back to reference M.Y. Do, Y. Rhee, D.J. Kim, C.S. Kim, K.H. Nam, C.W. Ahn et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocr. J. 52, 701–707 (2005)CrossRefPubMed M.Y. Do, Y. Rhee, D.J. Kim, C.S. Kim, K.H. Nam, C.W. Ahn et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocr. J. 52, 701–707 (2005)CrossRefPubMed
27.
go back to reference S.W. Cho, H.S. Choi, G.J. Yeom, J.A. Lim, J.H. Moon, D.J. Park et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid 24, 277–286 (2014)CrossRefPubMedPubMedCentral S.W. Cho, H.S. Choi, G.J. Yeom, J.A. Lim, J.H. Moon, D.J. Park et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid 24, 277–286 (2014)CrossRefPubMedPubMedCentral
28.
go back to reference G. Riesco-Eizaguirre, P. Gutierrez-Martinez, M.A. Garcia-Cabezas, M. Nistal, P. Santisteban, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na + /I- targeting to the membrane. Endocr. Relat. Cancer 13, 257–269 (2006)CrossRefPubMed G. Riesco-Eizaguirre, P. Gutierrez-Martinez, M.A. Garcia-Cabezas, M. Nistal, P. Santisteban, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na + /I- targeting to the membrane. Endocr. Relat. Cancer 13, 257–269 (2006)CrossRefPubMed
29.
go back to reference Y.M. Choi, W.G. Kim, H. Kwoon, M.J. Jeon, J.J. Lee, J.S. Ryu et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur. J. End. 175, 165–172 (2016)CrossRef Y.M. Choi, W.G. Kim, H. Kwoon, M.J. Jeon, J.J. Lee, J.S. Ryu et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur. J. End. 175, 165–172 (2016)CrossRef
30.
go back to reference E. Hindie, P. Zanotti-Fregonara, I. Keller, F. Duron, J.Y. Devaux, M. Calzada-Nocaudie et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr. Relat. Cancer 14, 799–807 (2007)CrossRefPubMed E. Hindie, P. Zanotti-Fregonara, I. Keller, F. Duron, J.Y. Devaux, M. Calzada-Nocaudie et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr. Relat. Cancer 14, 799–807 (2007)CrossRefPubMed
31.
go back to reference E. Robenshtok, A. Farooki, R.K. Grewal, R.M. Tuttle, Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. Endocrine 47, 266–272 (2014)CrossRefPubMed E. Robenshtok, A. Farooki, R.K. Grewal, R.M. Tuttle, Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. Endocrine 47, 266–272 (2014)CrossRefPubMed
Metadata
Title
Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer
Authors
Domenico Albano
Maria Beatrice Panarotto
Rexhep Durmo
Carlo Rodella
Francesco Bertagna
Raffaele Giubbini
Publication date
01-01-2019
Publisher
Springer US
Published in
Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1713-2

Other articles of this Issue 1/2019

Endocrine 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.